Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
| MarketCap | 1.3B |
|---|---|
| PE Ratio | -2.7 |
| PEG Ratio | 0.2 |
| P/B | 15.7 |
| P/S (ttm) | 1051.0 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 13% |
| Held by Institutions % | 95% |
| 1 Day Vol Adjusted Return | -0.3 |
| 1 Month Vol Adjusted Return | 6.2 |
| 3 Month Vol Adjusted Return | -2.6 |
| 6 Month Vol Adjusted Return | 0.5 |
| 20 Days SMA Price ZScore | 1.0 |
| 50 Days SMA Price ZScore | 0.5 |
| 12 -26 Days PPO | 2.0 |
| 1 Month Average Short Volume Ratio | 44.3 |
| 1 Day Volume Change ZScore | -1.5 |
| 1 Month Daily Vol | 5.3 |
Stock news
PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9 at 3:00 pm PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the In
- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and urinary calcium concentrations over a 24 week treatment period in patients with autosomal dominant hypocalcemia type 1 (ADH1) - The primary composite endpoint evaluates the proportion of participants with ADH1 achieving blood and urinary calcium within widely accepted normal ranges - In an ongoing single arm, open-label, Phase 2 saf
It's not possible to invest over long periods without making some bad investments. But really big losses can really...
Led by a veteran of BridgeBio, the virtual company isn't saying much about the targets of its drugs, which were spun over to it by Paragon Therapeutics.
A new startup is spinning out of Waltham-based antibody discovery company Paragon Therapeutics to develop new approaches to treating immunological and inflammatory diseases.
PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: Jefferies Health Care Conference, London, UK: November 15th at 9:40 am ETEvercore ISI HealthCONx Conference, Virtual: November 30th at 10:05 am ET To access the live webcast
BridgeBio Pharma ( NASDAQ:BBIO ) Third Quarter 2022 Results Key Financial Results Revenue: US$338.0k (down 86% from 3Q...
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 8.82% and 94.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Reported positive preclinical data for its next-generation KRASG12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism in late lead optimization - Reported positive updated 12-month Phase 2 data for BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i - Enrolled Cohort 5 of Phase 2 trial of infigratinib in achondroplasia, with no serious adverse events (SAEs), and no adverse events that required dose modifications reported to date - Reported dosi
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.